Abstract
Metabolomics is a recently emerging member of the “omics” technologies. It aims at detecting and quantifying all detectable small molecules, the so-called metabolites, present in a biological sample. Because of the lower number of metabolites compared with the number of genes and proteins identified in genomics and proteomics approaches, data of metabolic studies are less complex and may therefore be more informative. Metabolomics may thus significantly contribute to our understanding of disease mechanisms. Autoimmune diseases are of growing clinical relevance, and due to the chronic nature of these diseases successful treatment is often challenging. In the past years, a variety of studies have been published about the metabolome of autoimmune diseases such as Crohn ’ s disease and rheumatoid arthritis. However, our understanding of the role of different metabolites in the pathogenesis of autoimmune diseases is still far from being complete.
Keywords: Autoimmunity, Crohn's disease, rheumatoid arthritis, metabolomics
Current Drug Discovery Technologies
Title: Metabolic Changes in Autoimmune Diseases
Volume: 6 Issue: 4
Author(s): Karsten Seeger
Affiliation:
Keywords: Autoimmunity, Crohn's disease, rheumatoid arthritis, metabolomics
Abstract: Metabolomics is a recently emerging member of the “omics” technologies. It aims at detecting and quantifying all detectable small molecules, the so-called metabolites, present in a biological sample. Because of the lower number of metabolites compared with the number of genes and proteins identified in genomics and proteomics approaches, data of metabolic studies are less complex and may therefore be more informative. Metabolomics may thus significantly contribute to our understanding of disease mechanisms. Autoimmune diseases are of growing clinical relevance, and due to the chronic nature of these diseases successful treatment is often challenging. In the past years, a variety of studies have been published about the metabolome of autoimmune diseases such as Crohn ’ s disease and rheumatoid arthritis. However, our understanding of the role of different metabolites in the pathogenesis of autoimmune diseases is still far from being complete.
Export Options
About this article
Cite this article as:
Seeger Karsten, Metabolic Changes in Autoimmune Diseases, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869074
DOI https://dx.doi.org/10.2174/157016309789869074 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors
Current Drug Targets Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design The Role of HLA Promoters in Autoimmunity
Current Pharmaceutical Design Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Genetic Susceptibility to Autoimmune Disorders: Clues from Gene Association and Gene Expression Studies
Current Molecular Medicine Chemokines as Drug Targets in Type 1 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Molecular Characteristics of Autoimmune Pancreatitis
Current Pharmaceutical Design Current and Potential Agents for the Treatment of Alopecia Areata
Current Pharmaceutical Design Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?
Inflammation & Allergy - Drug Targets (Discontinued)